Tag Archives: China
By Pharm Exec | Published: March 21, 2014
Supply chains risks in China still include extremely high levels of corruption, environmental pollution issues and slow working conditions reforms, according to new analysis from Sedex.
By Julian Upton | Published: February 26, 2014
Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.
By Ben Comer | Published: February 6, 2014
Pharma industry executives, FDA officials and Department of Justice attorneys speaking last week at CBI’s 11th annual Pharmaceutical Compliance Congress (PCC) offered solutions and threats to companies hoping to avoid enforcement actions.
By Pharm Exec | Published: January 28, 2014
The gastrointestinal (GI) therapeutics market for Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD) in the Asia-Pacific (APAC) region will increase in value from $564m in 2012 to $784m by 2019 (a CAGR of 4.8%), according to a new report from GBI Research.
By Julian Upton | Published: January 21, 2014
While the tide has been turning for pharma in the BRIC markets, they will continue to be important but only if the industry has learnt the hard lessons of the last few years. Speaking to Pharm Exec for the 2014 Industry Outlook, Reenita Das, Partner at Frost & Sullivan, says its now more important than […]